Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

Company Overview

Agios Pharmaceuticals, Inc. is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations. Tibsovo (ivosidenib) is approved for treating relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation and for certain advanced cholangiocarcinoma patients. Idhifa (enasidenib) addresses AML patients bearing an IDH2 mutation. These targeted therapies represent some of the first metabolism-based oncology treatments on the market.

Beyond its approved products, Agios maintains a diverse pipeline in both oncology and rare genetic diseases. The company is developing mitapivat, a pyruvate kinase activator for chronic hemolytic anemias, in collaboration with Servier for ex-U.S. commercialization. Additional research programs leverage Agios’s expertise in metabolic targets to pursue next-generation candidates for hematologic malignancies and solid tumors. Agios markets its therapies directly in the United States and partners with global pharmaceutical companies for commercialization in Europe and other regions.

Agios went public in 2013 and has maintained its headquarters and core research operations in Cambridge. Leadership is currently headed by President and CEO Jackie Fouse, with Catherine Shacklett serving as Chief Financial Officer. The company continues to expand its scientific capabilities and strategic collaborations as it advances its mission of translating metabolism research into life-changing treatments.

Key Stats

• Today's Range: $36.68 to $38.02
• 50-Day Range: $35.00 to $40.61
• 52-Week Range: $23.42 to $62.58
• Volume: 650,783 shs
• Average Volume: 718,370 shs
• Market Capitalization: $2.20 billion
• P/E Ratio: 3.45
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Moderate Buy

Agios Pharmaceuticals Stock Analysis - MarketRank™

Agios Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 142nd out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Agios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Agios Pharmaceuticals has a consensus price target of $56.00, representing about 50.0% upside from its current price of $37.33.

Amount of Analyst Coverage

Agios Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.85) to ($5.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Agios Pharmaceuticals is 3.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of Agios Pharmaceuticals is 3.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.86.

Price to Book Value per Share Ratio

Agios Pharmaceuticals has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.75% of the float of Agios Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Agios Pharmaceuticals has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Agios Pharmaceuticals has recently decreased by 1.24%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Agios Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Agios Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.13

Percentage of Shares Shorted

8.75% of the float of Agios Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Agios Pharmaceuticals has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Agios Pharmaceuticals has recently decreased by 1.24%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.43

News Sentiment

Agios Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Agios Pharmaceuticals this week, compared to 7 articles on an average week.

Search Interest

Only 2 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,341,232.00 in company stock.

Percentage Held by Insiders

Only 4.30% of the stock of Agios Pharmaceuticals is held by insiders.

AGIO Stock Analysis - Frequently Asked Questions

How have AGIO shares performed this year?

Agios Pharmaceuticals' stock was trading at $32.86 at the beginning of the year. Since then, AGIO stock has increased by 13.6% and is now trading at $37.3290.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted its earnings results on Thursday, July, 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts' consensus estimates of ($1.74) by $0.19. The biopharmaceutical company earned $12.50 million during the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative trailing twelve-month return on equity of 3.49%.
Read the conference call transcript.

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' top institutional shareholders include Bellevue Group AG (6.18%), Commodore Capital LP (4.00%), State Street Corp (3.36%) and Geode Capital Management LLC (2.42%). Insiders that own company stock include Jacqualyn A Fouse, Brian Goff, Sarah Gheuens, Cecilia Jones, James William Burns, Tsveta Milanova, David Scadden, Kaye I Foster-Cheek and Theodore James Jr Washburn.
View institutional ownership trends.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 9/18/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AGIO
• CIK: 1439222
• Web: www.agios.com
• Phone: (617) 649-8600
• Fax: N/A
• Employees: 390
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Agios Pharmaceuticals: $56.00
• High Price Target: $65.00
• Low Price Target: $51.00
• Potential Upside/Downside: +47.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $11.00
• Trailing P/E Ratio: 3.45
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $673.72 million
• Net Margins: 1,590.42%
• Pretax Margin: 1,698.66%
• Return on Equity: -3.49%
• Return on Assets: -3.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.48
• Quick Ratio: 14.04

Sales & Book Value

• Annual Sales: $40.88 million
• Price / Sales: 53.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $27.02 per share
• Price / Book: 1.40

Miscellaneous

• Outstanding Shares: 58,102,000
• Free Float: 55,604,000
• Market Cap: $2.20 billion
• Optionable: Optionable
• Beta: 0.87